Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 14/20 | 0.67 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 5/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637409 | 1.00 | OGA (0.67) | OGASIAHCYADORA2B | |
| SCHEMBL2637488 | 0.81 | OGA (0.63) | OGASI | |
| SCHEMBL2637280 | 0.80 | OGA (1.00) | OGASI | |
| SCHEMBL2637505 | 0.80 | OGA (0.67) | OGASI | |
| SCHEMBL15061582 | 0.80 | OGA (1.00) | OGASI | |
| SCHEMBL13353993 | 0.80 | OGA (1.00) | OGASI | |
| SCHEMBL13321843 | 0.80 | OGA (1.00) | OGASI | |
| SCHEMBL2637452 | 0.80 | OGA (1.00) | OGASI | |
| SCHEMBL12183854 | 0.78 | OGA (0.60) | OGASI | |
| SCHEMBL2637380 | 0.78 | OGA (0.68) | OGASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569291-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | UNIV FRASER SIMON (CA) | 2016-04-06 | — | — | EP | claimed |
| US-9120781-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-09-01 | — | — | US | claimed |
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-05-23 | — | — | US | claimed |
| EP-2569291-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Simon Fraser University (CA) | 2013-03-20 | — | — | EP | claimed |
| WO-2011140640-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2011-11-17 | — | — | WO | claimed |
| EP-2569291-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | UNIV FRASER SIMON (CA) | 2016-04-06 | — | — | EP | disclosed |
| EP-2569291-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | UNIV FRASER SIMON (CA) | 2016-04-06 | — | — | EP | disclosed |
| US-9120781-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-09-01 | — | — | US | disclosed |
| US-9120781-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-09-01 | — | — | US | disclosed |
| US-9120781-B2 | Selective glycosidase inhibitors and uses thereof | SIMON FRASER UNIVERSITY (CA) | 2015-09-01 | — | — | US | disclosed |
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-05-23 | — | — | US | disclosed |
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-05-23 | — | — | US | disclosed |
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2013-05-23 | — | — | US | disclosed |
| EP-2569291-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Simon Fraser University (CA) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011140640-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011140640-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131044-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ENGASE, OGA, GALE | OGA 2/4885SI 74/4885AHCY 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.